Addendum
Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31
Report documents
-
Addendum
Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31
Dossier assessment
Indication:
Adult patients with metastatic non-small cell lung cancer with no sensitizing EGFR mutations or ALK-positive mutations; first-line treatment
Result of dossier assessment:
Unchanged after addendum:
- PD-L1 expression ≥ 50%: added benefit not proven
- PD-L1 expression < 50%: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
05-10-2023 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A23-84
- Commission
- Commission awarded on 09.08.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31
Status: Commission completed